Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 317 of the 333 references it cites were found in a registry or an index.

Frontotemporal lobar degeneration

Open access

Abstract

Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset dementia and presents with early social-emotional-behavioural and/or language changes that can be accompanied by a pyramidal or extrapyramidal motor disorder. About 20-25% of individuals with FTLD are estimated to carry a mutation associated with a specific FTLD pathology. The discovery of these mutations has led to important advances in potentially disease-modifying treatments that aim to slow progression or delay disease onset and has improved understanding of brain functioning. In both mutation carriers and those with sporadic disease, the most common underlying diagnoses are linked to neuronal and glial inclusions containing tau (FTLD-tau) or TDP-43 (FTLD-TDP), although 5-10% of patients may have inclusions containing proteins from the FUS-Ewing sarcoma-TAF15 family (FTLD-FET). Biomarkers definitively identifying specific pathological entities in sporadic disease have been elusive, which has impeded development of disease-modifying treatments. Nevertheless, disease-monitoring biofluid and imaging biomarkers are becoming increasingly sophisticated and are likely to serve as useful measures of treatment response during trials of disease-modifying treatments. Symptomatic trials using novel approaches such as transcranial direct current stimulation are also beginning to show promise.

Overview

CoChat Summary

TL;DR

Frontotemporal lobar degeneration (FTLD) is described as a major cause of early-onset dementia with early behavioral, language, and sometimes motor changes. This review highlights that about 20–25% of cases carry a pathogenic mutation, while biomarker and treatment development remain challenging but are advancing.

Key findings

  • FTLD is “one of the most common causes of early-onset dementia” and presents with early social-emotional-behavioural and/or language changes, sometimes with pyramidal or extrapyramidal motor disorder.
  • About 20–25% of individuals with FTLD are estimated to carry a mutation associated with a specific FTLD pathology.
  • The most common underlying pathological diagnoses are FTLD-tau and FTLD-TDP; about 5–10% of patients may have FTLD-FET.
  • The paper states that biomarker identification of specific pathology in sporadic disease has been elusive, but biofluid and imaging biomarkers are becoming more sophisticated and may help monitor treatment response; symptomatic trials such as transcranial direct current stimulation are “beginning to show promise.”

Methods

  • Review article (Nature Reviews Disease Primers) synthesizing the FTLD literature; no original study design is stated.
  • No sample, cohort, or dataset is described in the provided text.
  • Main analysis is narrative review and expert synthesis of disease presentation, genetics, pathology, biomarkers, and emerging therapies.

Limitations

  • The text states that biomarkers definitively identifying specific pathological entities in sporadic disease have been elusive, which has impeded development of disease-modifying treatments.
  • No formal study limitations are stated in the paper text provided.
  • As a review, it does not present original primary data or a new cohort for direct inference (evident from the text).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41572-023-00447-0

Cites

317 of 317 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 0 Not checked · 8 Own results and interpretations

  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 333 references

Research works printed but not linked: 2

  1. Logsdon, R. G., Gibbons, L., McCurry, S. M. & Teri, L. Quality of life in Alzheimer’s disease: patient and caregiver reports. J. Ment. Health Aging 5, 21–32 (1999).
  2. Deleon, J. & Miller, B. L. in Neurogenetics, Part II (eds Geschwind, D. H., Paulson, H. L. & Klein, C.) 409–430 (Elsevier, 2018). [Series Eds Aminoff, M. J., Boller, F. & Swaab, D. F. Handbook of Clinical Neurology Vol. 148].

Cited by

See all 183

Metadata

Authors
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., Zetterberg, H., & van Swieten, J. C.
Affiliations
  • University of Pennsylvania (US)
  • University of California, San Francisco (US)
  • Johns Hopkins University (US)
  • Mayo Clinic (US)
  • The University of Sydney (AU)
  • University of Antwerp (BE)
  • University of Wisconsin–Madison (US)
Corresponding author
Seeley, William W.
Venue
Nature Reviews Disease Primers
Published
2023-08-10
Volume
9
Issue
1
Pages
40-40
ISSN
2056-676X (ISSN-L)
OpenAlex
W4385721201
Cited by
178
References
333
Citations by year
2026: 62 · 2025: 61 · 2024: 49 · 2023: 6
FWCI
8.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Disease Primers (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Biogen
  • Regeneron Pharmaceuticals
  • University of Cambridge
  • European Commission (101,053,962, ALFGBG-71320)
  • Eisai
  • Vetenskapsrådet (#101053962, 2022-01018, ALFGBG‐71320, 2019-02397)
  • National Institutes of Health (AG066597)
  • HORIZON EUROPE Framework Programme (101053962)
  • Medical Research Council
  • National Health and Medical Research Council (2008020)
  • National Institute on Aging (AG066597)
  • National Institute on Deafness and Other Communication Disorders (R01DC014942, R01DC012519)
  • National Institute of Neurological Disorders and Stroke (RF1NS112153, R01NS089757)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
frontotemporal lobar degeneration, early-onset dementia, FTLD-tau, FTLD-TDP, tau inclusions, TDP-43 inclusions, genetic mutations, disease-modifying therapy, biomarkers, biofluid biomarkers, neuroimaging biomarkers, transcranial direct current stimulation, motor disorders
MeSH terms
Humans, Biomarkers, Frontotemporal Lobar Degeneration, Frontotemporal Dementia, Transcranial Direct Current Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Frontotemporal lobar degeneration. https://app.cochat.ai/papers/10.1038/s41572-023-00447-0
The paper
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., Zetterberg, H., & van Swieten, J. C. (2023). Frontotemporal lobar degeneration. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-023-00447-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.